+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Schizophrenia - Pipeline Review, H2 2018

  • ID: 4662956
  • Drug Pipelines
  • 321 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BioStem Technologies Inc
  • Denovo Biopharma LLC
  • GW Pharmaceuticals Plc
  • KemPharm Inc
  • NeurOp Inc
  • MORE
Schizophrenia - Pipeline Review, H2 2018

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides an overview of the Schizophrenia (Central Nervous System) pipeline landscape.

Schizophrenia is a chronic, severe, and disabling brain disorder that generally appears in late adolescence or early adulthood. Symptoms include delusions, hallucinations, disorganized speech and disorganized behavior. Risk factors include family history, age, drugs (psychoactive) and weakened immune system. Treatment includes antipsychotic medications.

Report Highlights

This latest pipeline guide Schizophrenia - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Schizophrenia (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Schizophrenia (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 1, 13, 14, 18, 3, 53, 12 and 1 respectively. Similarly, the Universities portfolio in Phase II, Phase I, Preclinical and Discovery stages comprises 1, 1, 7 and 1 molecules, respectively.

Schizophrenia (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Schizophrenia (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Schizophrenia (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Schizophrenia (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Schizophrenia (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Schizophrenia (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Schizophrenia (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Schizophrenia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • BioStem Technologies Inc
  • Denovo Biopharma LLC
  • GW Pharmaceuticals Plc
  • KemPharm Inc
  • NeurOp Inc
  • MORE
Introduction

Schizophrenia - Overview

Schizophrenia - Therapeutics Development

Schizophrenia - Therapeutics Assessment

Schizophrenia - Companies Involved in Therapeutics Development

Schizophrenia - Drug Profiles

Schizophrenia - Dormant Projects

Schizophrenia - Discontinued Products

Schizophrenia - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Schizophrenia - Pipeline by AbbVie Inc, H2 2018

Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by Adamed Sp z oo, H2 2018

Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by AgeneBio Inc, H2 2018

Schizophrenia - Pipeline by Alkermes Plc, H2 2018

Schizophrenia - Pipeline by Athersys Inc, H2 2018

Schizophrenia - Pipeline by Avanir Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by Avineuro Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by BCWorld Pharm Co Ltd, H2 2018

Schizophrenia - Pipeline by BioHealthonomics Inc, H2 2018

Schizophrenia - Pipeline by BioStem Technologies Inc, H2 2018

Schizophrenia - Pipeline by BioXcel Therapeutics Inc, H2 2018

Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H2 2018

Schizophrenia - Pipeline by Bristol-Myers Squibb Co, H2 2018

Schizophrenia - Pipeline by Cerevance Inc, H2 2018

Schizophrenia - Pipeline by Concert Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by Curemark LLC, H2 2018

Schizophrenia - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2018

Schizophrenia - Pipeline by Delpor Inc, H2 2018

Schizophrenia - Pipeline by Denovo Biopharma LLC, H2 2018

Schizophrenia - Pipeline by DURECT Corp, H2 2018

Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd, H2 2018

Schizophrenia - Pipeline by Fabre-Kramer Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by Gabather AB, H2 2018

Schizophrenia - Pipeline by Genentech Inc, H2 2018

Schizophrenia - Pipeline by GlaxoSmithKline Plc, H2 2018

Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd, H2 2018

Schizophrenia - Pipeline by GP Pharm SA, H2 2018

Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H2 2018

Schizophrenia - Pipeline by H. Lundbeck AS, H2 2018

Schizophrenia - Pipeline by Heptares Therapeutics Ltd, H2 2018

Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co Inc, H2 2018

Schizophrenia - Pipeline by Impel NeuroPharma Inc, H2 2018

Schizophrenia - Pipeline by Insys Therapeutics Inc, H2 2018

Schizophrenia - Pipeline by Intra-Cellular Therapies Inc, H2 2018

Schizophrenia - Pipeline by IRLAB Therapeutics AB, H2 2018

Schizophrenia - Pipeline by Johnson & Johnson, H2 2018

Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc, H2 2018

Schizophrenia - Pipeline by KemPharm Inc, H2 2018

List of Figures

Number of Products under Development for Schizophrenia, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Acadia Pharmaceuticals Inc
  • Adamed Sp z oo
  • Aequus Pharmaceuticals Inc
  • AgeneBio Inc
  • Alkermes Plc
  • Athersys Inc
  • Avanir Pharmaceuticals Inc
  • Avineuro Pharmaceuticals Inc
  • BCWorld Pharm Co Ltd
  • BioHealthonomics Inc
  • BioStem Technologies Inc
  • BioXcel Therapeutics Inc
  • Boehringer Ingelheim GmbH
  • Bristol-Myers Squibb Co
  • Cerevance Inc
  • Concert Pharmaceuticals Inc
  • Curemark LLC
  • Daewoong Pharmaceutical Co Ltd
  • Delpor Inc
  • Denovo Biopharma LLC
  • DURECT Corp
  • F. Hoffmann-La Roche Ltd
  • Fabre-Kramer Pharmaceuticals Inc
  • Gabather AB
  • Genentech Inc
  • GlaxoSmithKline Plc
  • Glenmark Pharmaceuticals Ltd
  • GP Pharm SA
  • GW Pharmaceuticals Plc
  • H. Lundbeck AS
  • Heptares Therapeutics Ltd
  • Hisamitsu Pharmaceutical Co Inc
  • Impel NeuroPharma Inc
  • Insys Therapeutics Inc
  • Intra-Cellular Therapies Inc
  • IRLAB Therapeutics AB
  • Johnson & Johnson
  • Karuna Pharmaceuticals Inc
  • KemPharm Inc
  • Laboratorios Farmaceuticos Rovi SA
  • Lead Discovery Center GmbH
  • LifeMax Laboratories Inc
  • Lohocla Research Corp
  • Luye Pharma Group Ltd
  • Mapi Pharma Ltd
  • MedinCell SA
  • Merck & Co Inc
  • Mitsubishi Tanabe Pharma Corp
  • Neurocrine Biosciences Inc
  • NeurOp Inc
  • Newron Pharmaceuticals SpA
  • Omeros Corp
  • Otsuka Holdings Co Ltd
  • Pfizer Inc
  • Ra Pharmaceuticals Inc
  • Reviva Pharmaceuticals Inc
  • Richter Gedeon Nyrt
  • Sage Therapeutics Inc
  • Sichuan Kelun Pharmaceutical Co Ltd
  • SkySea Pharmaceutical Inc
  • Sumitomo Dainippon Pharma Co Ltd
  • Sunovion Pharmaceuticals Inc
  • Taisho Pharmaceutical Holdings Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Tetra Discovery Partners LLC
  • Teva Pharmaceutical Industries Ltd
  • Vanda Pharmaceuticals Inc
  • Vitality Biopharma Inc
  • VLP Therapeutics LLC
  • Zysis Ltd
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4662956
Adroll
adroll